Indivior Pharmaceuticals Inc.
11/03/2026 | Press release | Distributed by Public on 11/03/2026 08:11
Material Event (Form 8-K)
Item 8.01 Other.
Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the "Company" or the "Registrant") and U.S. Bank Trust Company, National Association (the "Indenture"), governing the Company's 0.625% Convertible Senior Notes due 2031 (the "Notes"), as a result of the Special Dividend that was declared by the Company's board on September 16, 2026, the conversion rate per $1,000 principal amount of Notes has been increased from 24.0033 shares of the Company's common stock to 30.9355 shares of the Company's common stock, which reflects a conversion price of approximately $32.33 per share. The conversion rate is subject to customary adjustments upon the occurrence of certain events as described in the Indenture. No bondholders converted their bonds for common stock.
Indivior Pharmaceuticals Inc. published this content on November 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 03, 2026 at 14:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]